Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab + SOX versus placebo + SOX as perioperative therapy for resectable gastric/gastroesophageal junction adenocarcinoma
CTR20252052Phase 3Active
- Sponsor
- Akeso, Inc.
- Start
- Aug 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of cadonilimab in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Akeso, Inc.. Started Aug 2025; status: active.
02
Drugs
cadonilimab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on CTR20252052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20252052.